Breast cancer in elderly women (> or = 70 years): which treatment?
Breast cancer is a disease that affects women >70 years of age much more frequently than other age groups. Epidemiologic data show that more than 40% of breast cancers occur in the elderly. The optimal primary treatment for elderly patients with breast cancer is controversial and ranges from tamoxifen as sole therapy to surgery. Despite the high prevalence of the disease, the elderly have been excluded from clinical trials mainly for the presence of concurrent medical conditions that adversely affect treatment strategies. Since life expectancy continues to increase in western countries, an appropriate treatment that respects quality of life needs to be determined for the elderly age group. In the light of randomised and retrospective studies carried out to date, limited surgery without axillary dissection plus adjuvant tamoxifen seems to achieve, mainly for elderly patients with early stage breast cancer, a local-regional control rate comparable to that obtained with more aggressive therapeutic strategies. The results of ongoing prospective clinical trials will show whether or not conservative surgery without axillary clearance and tamoxifen may be routinely used for elderly patients with early breast cancer.
Martelli
G
G
Divisione Semeiotica Chirurgica, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
De Palo
G
G
D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008207:Lymphatic Metastasis; D008408:Mastectomy / Q000379:methods; D009364:Neoplasm Recurrence, Local; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen